FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098492855> ?p ?o ?g. }

• W2098492855 endingPage "1503" @default.
• W2098492855 startingPage "1498" @default.
• W2098492855 abstract "High-dose Interferon-α-2b (HD-IFN) is an adjuvant treatment for melanoma. However, clinical trials for HD-IFN have not been reported in acral melanoma (AM), the predominant subtype of cutaneous melanoma in Asian population.Patients with resected high-risk (stage IIb-IIIc) AM were randomly assigned to a regimen of 4-week (arm A: 15 × 10(6)U/m(2)d1-5/w × 4w) or 1-year adjuvant HD-IFN (arm B: 15 × 10(6)U/m(2)d1-5/w × 4w+9 × 10(6)Utiw × 48w), respectively. The endpoints were relapse-free survival (RFS), overall survival (OS) and toxicities.A total of 158 patients were enrolled in this study and 147 patients were eligible for survival analysis. With a median follow-up of 36.1 months, median RFS for arm A and arm B were 17.9 months and 22.5 months, respectively (P=0.72). Stratified analysis showed that RFS curves of patients in stage IIIb-IIIc were statistically different between arm A and arm B (P=0.02). The median RFS of patients with more nodal metastases (n⩾3) was shorter (P=0.004) in arm A (3.3 months) than that in arm B (11.9 months). Grade 1/2 adverse effects were observed in both groups. However, patients in arm B showed higher incidence of reversible Grade 3/4 hepatotoxicity (P=0.03).The induction dose of 15 × 10(6)U/m(2) and the maintenance dose of 9 × 10(6)U were tolerable, which may be the optional dose intensity for adjuvant IFN-α-2b therapy in Chinese high risk AM population. No statistical significance was detected in RFS between the 4-week and 1-year regimen while a 1-year regimen may show clinical benefits in patients with stage IIIb-IIIc AM or with ≥ 3 nodal metastases." @default.
• W2098492855 created "2016-06-24" @default.
• W2098492855 creator A5007562507 @default.
• W2098492855 creator A5009201250 @default.
• W2098492855 creator A5018372804 @default.
• W2098492855 creator A5034855042 @default.
• W2098492855 creator A5035685296 @default.
• W2098492855 creator A5047115795 @default.
• W2098492855 creator A5069813415 @default.
• W2098492855 creator A5084636770 @default.
• W2098492855 date "2011-07-01" @default.
• W2098492855 modified "2023-10-06" @default.
• W2098492855 title "A randomised phase II trial of 1month versus 1year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients" @default.
• W2098492855 cites W1819917384 @default.
• W2098492855 cites W1828940258 @default.
• W2098492855 cites W1855551203 @default.
• W2098492855 cites W1908752382 @default.
• W2098492855 cites W1981218605 @default.
• W2098492855 cites W1988818903 @default.
• W2098492855 cites W1990435553 @default.
• W2098492855 cites W1993679893 @default.
• W2098492855 cites W2004563850 @default.
• W2098492855 cites W2015234005 @default.
• W2098492855 cites W2021910372 @default.
• W2098492855 cites W2023999559 @default.
• W2098492855 cites W2056815872 @default.
• W2098492855 cites W2057469521 @default.
• W2098492855 cites W2060662007 @default.
• W2098492855 cites W2063054909 @default.
• W2098492855 cites W2063403309 @default.
• W2098492855 cites W2099289479 @default.
• W2098492855 cites W2117248396 @default.
• W2098492855 cites W2118449798 @default.
• W2098492855 cites W2125637479 @default.
• W2098492855 cites W2126367595 @default.
• W2098492855 cites W2131365547 @default.
• W2098492855 cites W2150698774 @default.
• W2098492855 cites W2160931905 @default.
• W2098492855 cites W2172075642 @default.
• W2098492855 cites W2327667520 @default.
• W2098492855 doi "https://doi.org/10.1016/j.ejca.2011.03.019" @default.
• W2098492855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21493058" @default.
• W2098492855 hasPublicationYear "2011" @default.
• W2098492855 type Work @default.
• W2098492855 sameAs 2098492855 @default.
• W2098492855 citedByCount "35" @default.
• W2098492855 countsByYear W20984928552012 @default.
• W2098492855 countsByYear W20984928552013 @default.
• W2098492855 countsByYear W20984928552014 @default.
• W2098492855 countsByYear W20984928552015 @default.
• W2098492855 countsByYear W20984928552016 @default.
• W2098492855 countsByYear W20984928552017 @default.
• W2098492855 countsByYear W20984928552018 @default.
• W2098492855 countsByYear W20984928552019 @default.
• W2098492855 countsByYear W20984928552020 @default.
• W2098492855 countsByYear W20984928552021 @default.
• W2098492855 countsByYear W20984928552022 @default.
• W2098492855 countsByYear W20984928552023 @default.
• W2098492855 crossrefType "journal-article" @default.
• W2098492855 hasAuthorship W2098492855A5007562507 @default.
• W2098492855 hasAuthorship W2098492855A5009201250 @default.
• W2098492855 hasAuthorship W2098492855A5018372804 @default.
• W2098492855 hasAuthorship W2098492855A5034855042 @default.
• W2098492855 hasAuthorship W2098492855A5035685296 @default.
• W2098492855 hasAuthorship W2098492855A5047115795 @default.
• W2098492855 hasAuthorship W2098492855A5069813415 @default.
• W2098492855 hasAuthorship W2098492855A5084636770 @default.
• W2098492855 hasConcept C120665830 @default.
• W2098492855 hasConcept C121332964 @default.
• W2098492855 hasConcept C126322002 @default.
• W2098492855 hasConcept C141071460 @default.
• W2098492855 hasConcept C168563851 @default.
• W2098492855 hasConcept C197934379 @default.
• W2098492855 hasConcept C203092338 @default.
• W2098492855 hasConcept C2777658100 @default.
• W2098492855 hasConcept C2777863537 @default.
• W2098492855 hasConcept C2781413609 @default.
• W2098492855 hasConcept C2908647359 @default.
• W2098492855 hasConcept C502942594 @default.
• W2098492855 hasConcept C61511704 @default.
• W2098492855 hasConcept C71924100 @default.
• W2098492855 hasConcept C90924648 @default.
• W2098492855 hasConcept C99454951 @default.
• W2098492855 hasConceptScore W2098492855C120665830 @default.
• W2098492855 hasConceptScore W2098492855C121332964 @default.
• W2098492855 hasConceptScore W2098492855C126322002 @default.
• W2098492855 hasConceptScore W2098492855C141071460 @default.
• W2098492855 hasConceptScore W2098492855C168563851 @default.
• W2098492855 hasConceptScore W2098492855C197934379 @default.
• W2098492855 hasConceptScore W2098492855C203092338 @default.
• W2098492855 hasConceptScore W2098492855C2777658100 @default.
• W2098492855 hasConceptScore W2098492855C2777863537 @default.
• W2098492855 hasConceptScore W2098492855C2781413609 @default.
• W2098492855 hasConceptScore W2098492855C2908647359 @default.
• W2098492855 hasConceptScore W2098492855C502942594 @default.
• W2098492855 hasConceptScore W2098492855C61511704 @default.
• W2098492855 hasConceptScore W2098492855C71924100 @default.
• W2098492855 hasConceptScore W2098492855C90924648 @default.

• next